Comparison · NCT00405392-sae
Ibandronate 150 mg Once Monthly vs Risedronate 35 mg Once Weekly: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ibandronate 150 mg Once Monthly vs Risedronate 35 mg Once Weekly: serious adverse events. Trial comparisons, record NCT00405392-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00405392-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0179 | 0.00821 | 0.0384 | wilson | |
| Risk in group 2 | 0.012 | 0.00467 | 0.0304 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00588 | -0.0149 | 0.0277 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.49 | 0.425 | 5.24 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.419 | 5.36 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ibandronate 150 mg Once Monthly than on Risedronate 35 mg Once Weekly | 170 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ibandronate 150 mg Once Monthly | Participants received ibandronate 150 mg tablet orally once in a month for 3 months either in period 1 or period 2 as per the randomization sequence. Participants were recommended to take the tablet on the same day every month in case of the once-monthly drug (e.g. on the 15th each month). The treatment was administered on an empty stomach in the morning, followed by an overnight fast (at least 6-hour fast). | 6 | 336 | EG000 |
| Group 2 | Risedronate 35 mg Once Weekly | Participants received risedronate 35 mg tablet orally once weekly for 12 weeks either in period 1 or period 2 as per the randomization sequence. Participants were recommended to take the tablet on the same day every month in case of the once-monthly drug (e.g. on the 15th each month). The treatment was administered on an empty stomach in the morning, followed by an overnight fast (at least 6-hour fast). | 4 | 334 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 6 months
Source ClinicalTrials.gov
Trial
- Title
- Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
- NCT number
- NCT00405392
- Phases
- PHASE4
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Ibandronate (SB743830HD)
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2018-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00405392?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00405392-sae